Preclinical Therapeutics Publications

Extensive conformational and physical plasticity protects HER2-HER3 tumorigenic signaling. Campbell MR, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, Sampang M, Jura N, Moasser MM. Cell Rep. 2022 Feb 1;38(5):110285.

Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers. Campbell MR, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, Littlefield P, Steri V, Oeffinger J, Sampang M, Shan Y, Shaw DE, Jura N, Moasser MM. Cell Rep. 2022 Feb 1;38(5):110291.

Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCβ1. Melnyk JE, Steri V, Nguyen HG, Hwang YC, Gordan JD, Hann B, Feng FY, Shokat KM.Oncogene. 2022 Jan 27. doi: 10.1038/s41388-022-02179-z

Surface Proteomics Reveals CD72 as a Target for In Vitro-Evolved Nanobody-Based CART Cells in KMT2A/MLL1-Rearranged B-ALL. Nix MA, Mandal K, Geng H, Paranjape N, Lin YT, Rivera JM, Marcoulis M, White KL, Whitman JD, Bapat SP, Parker KR, Ramirez J, Deucher A, Phojanokong P, Steri V, Fattahi F, Hann BC, Satpathy AT, Manglik A, Stieglitz E, Wiita AP. Cancer Discov. 2021 Aug;11(8):2032-2049.

FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma. Bigley AB, Spade S, Agha NH, Biswas S, Tang S, Malik MH, Dai L, Masoumi S, Patiño-Escobar B, Hale M, DiPierro G, Martell R, Hann B, Shah N, Wiita  AP, Liu X. Blood Adv. 2021 Aug 10;5(15):3021-3031.

Integrin αvβ8 on T cells suppresses anti-tumor immunity in multiple models and is a promising target for tumor immunotherapy. Dodagatta-Marri E, Ma HY, Liang B, Li J, Meyer DS, Chen SY, Sun KH, Ren X, Zivak B, Rosenblum MD, Headley MB, Pinzas L, Reed NI, Del Cid JS, Hann BC, Yang S, Giddabasappa A, Noorbehesht K, Yang B, Dal Porto J, Tsukui T, Niessen K, Atakilit A, Akhurst RJ, Sheppard D. Cell Rep. 2021 Jul 6;36(1):109309.

The role of HER2 and HER3 in HER2-amplified cancers beyond breast cancers. Majumder A, Sandhu M, Banerji D, Steri V, Olshen A, Moasser MM.Sci Rep. 2021 Apr 27;11(1):9091.

Transit-Amplifying Cells Coordinate Changes in Intestinal Epithelial Cell-Type Composition. Sanman LE, Chen IW, Bieber JM, Steri V, Trentesaux C, Hann B, Klein OD, Wu LF, Altschuler SJ.Dev Cell. 2021 Feb 8;56(3):356-365.e9.

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. Sherbenou DW, Su Y, Behrens CR, Aftab BT, Perez de Acha O, Murnane M, Bearrows SC, Hann BC, Wolf JL, Martin TG, Liu B. Clin Cancer Res. 2020 Nov 15;26(22):6028-6038.

The Splicing Modulator Sulfonamide Indisulam Reduces AR-V7 in Prostate Cancer Cells. Melnyk JE, Steri V, Nguyen HG, Hann B, Feng FY, Shokat KM. Bioorganic & Medicinal Chemistry. 2020 Aug 18.

Allosteric HSP70 inhibitors perturb mitochondrial proteostasis and overcome proteasome inhibitor resistance in multiple myeloma. Ferguson ID, Lin YT, Lam C, Shao H, Hale M,Tharp KM, Mariano MC, Steri V, Wang D, Phojanokong P, Tuomivaara ST, Hann B, Driessen C, Van Ness B, Gestwicki JE, Wiita AP. bioRxiv 2020.04.21.052456;

Proteasome inhibitor-induced modulation reveals the spliceosome as a specific therapeutic vulnerability in multiple myeloma. Huang HH, Ferguson ID, Thornton AM, Bastola P, Lam C, Lin YT, Choudhry P, Mariano MC, Marcoulis MD, Teo CF, Malato J, Phojanakong PJ, Martin TG 3rd, Wolf JL, Wong SW, Shah N, Hann B, Brooks AN, Wiita AP. Nat Commun. 2020 Apr 22;11(1):1931.

Evaluating the efficacy of multiple myeloma cell lines as models for patient tumors via transcriptomic correlation analysis. Sarin V, Yu K, Ferguson ID, Gugliemini O, Nix MA, Hann B, Sirota M, Wiita AP. Leukemia. 2020 Mar 2.

Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation. Elledge SK, Tran HL, Christian AH, Steri V, Hann B, Toste FD, Chang CJ, Wells JA. Proc Natl Acad Sci U S A. 2020 Mar 17;117(11):5733-5740.

Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes. Harel E, Shoji J, Abraham V, Miller L, Laszik ZG, King A, Dobi D, Szabo G, Hann B, Sarwal MM, Craik CS, Vincenti F. Transplantation. 2020 Jan;104(1):54-60.

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer. Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS. Antibodies (Basel). 2019 Nov 5;8(4).

A multi-modal data resource for investigating topographic heterogeneity in patient-derived xenograft tumors. Rajaram S, Roth MA, Malato J, VandenBerg S, Hann B, Atreya CE, Altschuler SJ, Wu LF. Sci Data. 2019 Oct 31;6(1):253.

Species-specific optimization of PEG~SN-38 prodrug pharmacokinetics and antitumor effects in a triple-negative BRCA1-deficient xenograft. Fontaine SD, Hann B, Reid R, Ashley GW, Santi DV. Cancer Chemother Pharmacol. 2019 Oct;84(4):729-738.

Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition. Scott GK, Yau C, Becker BC, Khateeb S, Mahoney S, Jensen MB, Hann B, Cowen BJ, Pegan SD, Benz CC. Mol Cancer Ther. 2019 Aug;18(8):1374-1385.

KRASG12C inhibition produces a driver-limited state revealing collateral dependencies. Lou K, Steri V, Ge AY, Hwang YC, Yogodzinski CH, Shkedi AR, Choi ALM, Mitchell DC, Swaney DL, Hann B, Gordan JD, Shokat KM, Gilbert LA. Sci Signal. 2019 May 28;12(583).

α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas. Dodagatta-Marri E, Meyer DS, Reeves MQ, Paniagua R, To MD, Binnewies M, Broz ML, Mori H, Wu D, Adoumie M, Del Rosario R, Li O, Buchmann T, Liang B, Malato J, Arce Vargus F, Sheppard D, Hann BC, Mirza A, Quezada SA, Rosenblum MD, Krummel MF, Balmain A, Akhurst RJ. J Immunother Cancer. 2019 Mar 4;7(1):62.

Identifying a potential biomarker for primary focal segmental glomerulosclerosis and its association with recurrence after transplantation. Harel E, Shoji J, Abraham V, Miller L, Laszik Z, Thurison T, King A, Olshen A, Leung J, Szabo G, Hann B, Høyer-Hansen G, Craik CS, Vincenti F. Clin Transplant. 2019 Mar;33(3):e13487.

A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors. Chamberlain CE, German MS, Yang K, Wang J, VanBrocklin H, Regan M, Shokat KM, Ducker GS, Kim GE, Hann B, Donner DB, Warren RS, Venook AP, Bergsland EK, Lee D, Wang Y, Nakakura EK. Mol Cancer Ther. 2018 Dec;17(12):2702-2709.

Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. JCI Insight. 2018 Sep 6;3(17).

Exploration of Benzothiazole Rhodacyanines as Allosteric Inhibitors of Protein-Protein Interactions with Heat Shock Protein 70 (Hsp70). Shao H, Li X, Moses MA, Gilbert LA, Kalyanaraman C, Young ZT, Chernova M, Journey SN, Weissman JS, Hann B, Jacobson MP, Neckers L, Gestwicki JE. J Med Chem. 2018 Jul 26;61(14):6163-6177.

Development of a stress response therapy targeting aggressive prostate cancer. Nguyen HG, Conn CS, Kye Y, Xue L, Forester CM, Cowan JE, Hsieh AC, Cunningham JT, Truillet C, Tameire F, Evans MJ, Evans CP, Yang JC, Hann B, Koumenis C, Walter P, Carroll PR, Ruggero D. Sci Transl Med. 2018 May 2;10(439).

Repurposing tofacitinib as an anti-myeloma therapeutic to reverse growth-promoting effects of the bone marrow microenvironment. Lam C, Ferguson ID, Mariano MC, Lin YT, Murnane M, Liu H, Smith GA, Wong SW, Taunton J, Liu JO, Mitsiades CS, Hann BC, Aftab BT, Wiita AP. Haematologica. 2018 Jul;103(7):1218-1228.

Heterogeneous drug penetrance of veliparib and carboplatin measured in triple negative breast tumors. Bartelink IH, Prideaux B, Krings G, Wilmes L, Lee PRE, Bo P, Hann B, Coppé JP, Heditsian D, Swigart-Brown L, Jones EF, Magnitsky S, Keizer RJ, de Vries N, Rosing H, Pawlowska N, Thomas S, Dhawan M, Aggarwal R, Munster PN, Esserman LJ, Ruan W, Wu AHB, Yee D, Dartois V, Savic RM, Wolf DM, van 't Veer L. Breast Cancer Res. 2017 Sep 11;19(1):107.

Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Aggarwal R, Behr SC, Paris PL, Truillet C, Parker MFL, Huynh LT, Wei J, Hann B, Youngren J, Huang J, Premasekharan G, Ranatunga N, Chang E, Gao KT, Ryan CJ, Small EJ, Evans MJ. Mol Cancer Res. 2017 Sep;15(9):1221-1229.

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. Cancer Res. 2017 Aug 15;77(16):4498-4505.

A Novel Tumor-Activated Prodrug Strategy Targeting Ferrous Iron Is Effective in Multiple Preclinical Cancer Models. Spangler B, Fontaine SD, Shi Y, Sambucetti L, Mattis AN, Hann B, Wells JA, Renslo AR. J Med Chem. 2016 Dec 22;59(24):11161-11170.

Antibody-drug conjugate targeting CD46 eliminates multiple myeloma cells. Sherbenou DW, Aftab BT, Su Y, Behrens CR, Wiita A, Logan AC, Acosta-Alvear D, Hann BC, Walter P, Shuman MA, Wu X, Atkinson JP, Wolf JL, Martin TG, Liu B. J Clin Invest. 2016 Dec 1;126(12):4640-4653.

ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC. Oncotarget. 2016 Oct 18;8(48):83432-83445.

TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response. Rozanov D, Cheltsov A, Sergienko E, Vasile S, Golubkov V, Aleshin AE, Levin T, Traer E, Hann B, Freimuth J, Alexeev N, Alekseyev MA, Budko SP, Bächinger HP, Spellman P. PLoS One. 2015 Jun 15;10(6):e0129566.

Validation of the Hsp70-Bag3 protein-protein interaction as a potential therapeutic target in cancer. Li X, Colvin T, Rauch JN, Acosta-Alvear D, Kampmann M, Dunyak B, Hann B, Aftab BT, Murnane M, Cho M, Walter P, Weissman JS, Sherman MY, Gestwicki JE. Mol Cancer Ther. 2015 Mar;14(3):642-8.

Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Sos ML, Levin RS, Gordan JD, Oses-Prieto JA, Webber JT, Salt M, Hann B, Burlingame AL, McCormick F, Bandyopadhyay S, Shokat KM. Cell Rep. 2014 Aug 21;8(4):1037-48.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Oncogene. 2014 Mar 20;33(12):1590-600.

Generation of a patient-derived chordoma xenograft and characterization of the phosphoproteome in a recurrent chordoma. Davies JM, Robinson AE, Cowdrey C, Mummaneni PV, Ducker GS, Shokat KM, Bollen A, Hann B, Phillips JJ. J Neurosurg. 2014 Feb;120(2):331-6.

Subtype-specific MEK-PI3 kinase feedback as a therapeutic target in pancreatic adenocarcinoma. Mirzoeva OK, Collisson EA, Schaefer PM, Hann B, Hom YK, Ko AH, Korn WM. Mol Cancer Ther. 2013 Oct;12(10):2213-25.

Pharmacological brake-release of mRNA translation enhances cognitive memory. Sidrauski C, Acosta-Alvear D, Khoutorsky A, Vedantham P, Hearn BR, Li H, Gamache K, Gallagher CM, Ang KK, Wilson C, Okreglak V, Ashkenazi A, Hann B, Nader K, Arkin MR, Renslo AR, Sonenberg N, Walter P. Elife. 2013 May 28;2:e00498.

Incomplete inhibition of phosphorylation of 4E-BP1 as a mechanism of primary resistance to ATP-competitive mTOR inhibitors. Ducker GS, Atreya CE, Simko JP, Hom YK, Matli MR, Benes CH, Hann B, Nakakura EK, Bergsland EK, Donner DB, Settleman J, Shokat KM, Warren RS. Oncogene. 2014 Mar 20;33(12):1590-600.

Targeting uPAR with antagonistic recombinant human antibodies in aggressive breast cancer. LeBeau AM, Duriseti S, Murphy ST, Pepin F, Hann B, Gray JW, VanBrocklin HF, Craik CS. Cancer Res. 2013 Apr 1;73(7):2070-81.

Imaging a functional tumorigenic biomarker in the transformed epithelium. LeBeau AM, Lee M, Murphy ST, Hann BC, Warren RS, Delos Santos R, Kurhanewicz J, Hanash SM, VanBrocklin HF, Craik CS. Proc Natl Acad Sci U S A. 2013 Jan 2;110(1):93-8.